Immunomodulating action of the 3-phenylcoumarin derivative 6,7-dihydroxy-3-3 ′,4′-methylenedioxyphenyl-coumarin in neutrophils from patients with rheumatoid arthritis and in rats with acute joint inflammation

ConclusionAltogether, the results reported herein indicate that 3-PD-5 is a promising modulator of the early stages of acute joint inflammation that can help to diminish not only excessive neutrophil infiltration in the synovia but also neutrophil activation and its outcomes in RA patients.
Source: Inflammation Research - Category: Research Source Type: research

Related Links:

AbstractThe Institute for Clinical and Economic Review (ICER) employs fixed cost-effectiveness (CE) thresholds that guide their appraisal of an intervention ’s long-term economic value. Given ICER’s rising influence in the healthcare field, we undertook an assessment of the concordance of ICER’s CE findings to the published CE findings from other research groups (i.e., “non-ICER” researchers including life science manufacturers, academics, and government institutions). Disease areas and pharmaceutical interventions for comparison were determined based on ICER evaluations conducted from 1 Janua...
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
AbstractPolymyalgia rheumatica (PMR) is a common rheumatological condition occurring in adults aged over 50  years. The association of PMR with other autoimmune diseases such as rheumatoid arthritis is complex. There is a clear relationship with giant cell arteritis. We sought to determine whether there is any association between PMR and idiopathic inflammatory myopathy (IIM). We undertook a database stu dy of adult patients with a diagnosis of IIM under the care of the Rheumatology Department of the Royal Adelaide Hospital, and retrospectively determined the frequency of PMR in this patient cohort. Patients were cons...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
This report contributes to a better understanding of MAP's controls over the immune cell response and mechanisms of MAP survival.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusion A great deal of progress is being made in the matter of treating aging: in advocacy, in funding, in the research and development. It can never be enough, and it can never be fast enough, given the enormous cost in suffering and lost lives. The longevity industry is really only just getting started in the grand scheme of things: it looks vast to those of us who followed the slow, halting progress in aging research that was the state of things a decade or two ago. But it is still tiny compared to the rest of the medical industry, and it remains the case that there is a great deal of work yet to be done at all...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusion A great deal of progress is being made in the matter of treating aging: in advocacy, in funding, in the research and development. It can never be enough, and it can never be fast enough, given the enormous cost in suffering and lost lives. The longevity industry is really only just getting started in the grand scheme of things: it looks vast to those of us who followed the slow, halting progress in aging research that was the state of things a decade or two ago. But it is still tiny compared to the rest of the medical industry, and it remains the case that there is a great deal of work yet to be done at all...
Source: Fight Aging! - Category: Research Authors: Tags: Of Interest Source Type: blogs
In this study, a novel thermosensitive liposome loaded with sinomenine hydrochloride (SIN-TSL) was developed by a pH gradient method. The SIN-TSL had a mean particle size of around 100 nm, and an high entrapment efficiency and drug loading capacity. The results also suggested that SIN-TSL had a thermosensitive drug release behaviour, with the drug release rate at 43 °C was much faster than the one at 37 °C. The SIN-TSL could be effectively taken up by lipopolysaccharide-activated HUVECs, without any cytotoxicity was observed. In addition, both in vitro and in vivo studies indicated that the SIN-TSL combined with mi...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
ObjectiveTo assess the risk of major adverse cardiovascular events (MACE) in patients with rheumatoid arthritis (RA) treated with tocilizumab compared to those treated with the tumor necrosis factor inhibitor etanercept.MethodsThis randomized, open ‐label, parallel‐group trial enrolled patients with active seropositive RA (n = 3,080) who had an inadequate response to conventional synthetic disease‐modifying antirheumatic drugs and who had at least 1 cardiovascular (CV) risk factor. Patients were randomly assigned 1:1 to receive open‐l abel tocilizumab at 8 mg/kg/month or etanercept at 50 mg/week. All pati...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Original Article Source Type: research
This report contributes t o a better understanding of MAP control of immune cells and its mechanisms of survival.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Bos taurus Source Type: research
Condition:   Arthritis, Rheumatoid Interventions:   Drug: Simvastatin 20 mg;   Drug: Methotrexate 10 mg Sponsor:   King Edward Medical University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arthritis | Cholesterol | Research | Rheumatoid Arthritis | Rheumatology | Soya